Lazard Asset Management LLC Grows Position in Relx Plc (NYSE:RELX)

Lazard Asset Management LLC grew its position in shares of Relx Plc (NYSE:RELX - Free Report) by 1.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,224,334 shares of the technology company's stock after purchasing an additional 48,793 shares during the quarter. Lazard Asset Management LLC owned approximately 0.23% of Relx worth $191,868,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Ameriprise Financial Inc. grew its position in Relx by 368.7% during the 4th quarter. Ameriprise Financial Inc. now owns 2,807,038 shares of the technology company's stock worth $127,437,000 after acquiring an additional 2,208,119 shares during the last quarter. Raymond James Financial Inc. bought a new position in Relx during the 4th quarter worth approximately $44,516,000. Northern Trust Corp grew its position in Relx by 51.6% during the 4th quarter. Northern Trust Corp now owns 2,191,588 shares of the technology company's stock worth $99,542,000 after acquiring an additional 745,532 shares during the last quarter. Bank of Montreal Can grew its position in Relx by 290.3% during the 4th quarter. Bank of Montreal Can now owns 886,758 shares of the technology company's stock worth $40,277,000 after acquiring an additional 659,547 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its position in Relx by 50.3% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,968,739 shares of the technology company's stock worth $89,420,000 after acquiring an additional 658,655 shares during the last quarter. 15.02% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

RELX has been the topic of several recent research reports. StockNews.com lowered Relx from a "buy" rating to a "hold" rating in a research report on Tuesday, March 4th. The Goldman Sachs Group initiated coverage on Relx in a research report on Wednesday, March 26th. They set a "buy" rating on the stock. Barclays upgraded Relx from an "equal weight" rating to an "overweight" rating in a research report on Friday, March 14th. Finally, Morgan Stanley reiterated an "overweight" rating on shares of Relx in a research report on Wednesday, April 16th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy".

Relx Trading Up 0.9%

Shares of RELX stock traded up $0.49 during trading hours on Friday, reaching $54.53. The company's stock had a trading volume of 432,311 shares, compared to its average volume of 706,582. The stock has a market capitalization of $100.92 billion, a P/E ratio of 29.32, a P/E/G ratio of 2.73 and a beta of 0.86. Relx Plc has a one year low of $43.28 and a one year high of $55.21. The firm's fifty day simple moving average is $51.14 and its 200 day simple moving average is $48.89. The company has a current ratio of 0.52, a quick ratio of 0.47 and a debt-to-equity ratio of 1.46.

Relx Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Wednesday, June 25th. Stockholders of record on Friday, May 9th will be given a $0.5586 dividend. This is a positive change from Relx's previous semi-annual dividend of $0.23. This represents a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, May 9th. Relx's dividend payout ratio (DPR) is currently 59.68%.

Relx Company Profile

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.